SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.

Key facts

Study ID

NCT00006013

Run by

Fox Chase Cancer Center

People needed

21

Starts

2000-06-01

Expected to finish

2003-01-01

Last updated by the study team

2013-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.